Polar Capital Holdings’s United Therapeutics UTHR Stock Holding History

Polar Capital Holdings’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-324,075	Closed	-$72.6M	–	311
2023 Q1	$72.6M	Sell	324,075 -818	-0.3%	-$202K	0.47%	61
2022 Q4	$90.3M	Buy	324,893 +4,062	+1%	+$1.03M	0.72%	38
2022 Q3	$67.2K	Buy	320,831 +15,678	+5%	+$3.51M	0.43%	61
2022 Q2	$71.9K	Sell	305,153 -68,227	-18%	-$13.9M	0.42%	62
2022 Q1	$67K	Sell	373,380 -152,287	-29%	-$29M	0.3%	80
2021 Q4	$114K	Buy	525,667 +432,211	+462%	+$84.8M	0.43%	46
2021 Q3	$17.3K	Buy	93,456 +43,627	+88%	+$8.59M	0.07%	183
2021 Q2	$8.94K	Buy	49,829 +41,355	+488%	+$7.88M	0.04%	237
2021 Q1	$1.42M	Buy	8,474 +5,191	+158%	+$866K	0.01%	285
2020 Q4	$498K	Buy	+3,283	New	+$431K	﹤0.01%	307

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Polar Capital Holdings's UTHR Position: Q2 2023 in Review

Polar Capital Holdings sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 324,075 shares — an estimated $72.6M sold.

Polar Capital Holdings first reported a position in UTHR in Q4 2020 and held it in 10 quarters. The position peaked at $90.3M in Q4 2022. 475 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Polar Capital Holdings reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
Polar Capital Holdings sold 324,075 United Therapeutics shares in Q2 2023, an estimated $72.6M.
Polar Capital Holdings first reported a position in United Therapeutics in Q4 2020 and held it in 10 quarters.
Polar Capital Holdings's United Therapeutics position peaked at $90.3M in Q4 2022.
475 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Polar Capital Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.